Bullfrog AI Holdings, Inc. Warrants(BFRGW)Earnings, Financials & Key Ratios

BFRGW•NASDAQ

$0.12

Price updated Jun 27, 2026

SectorHealthcare IndustryHealthcare IT Sub-IndustryLife Sciences and Precision Medicine Software

AboutBullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.Show more

Revenue$117K
EBITDA-$7M+8.9%
Net Income-$6M+7.1%
EPS (Diluted)-0.63+25.9%
Gross Margin17.29%
EBITDA Margin-5650.91%
Operating Margin-5652.38%
Net Margin-5569.61%
ROE-183.04%+1.1%

BFRGW Price & Volume

Bullfrog AI Holdings, Inc. Warrants (BFRGW) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Threaten Liquidity Runway Stability

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Liquidity and insolvency risk

Key Thesis Takeaways

Bullfrog AI Holdings faces a precarious financial outlook characterized by negligible commercial traction and a reliance on intermittent pilot-based consulting engagements.
The firm's inability to scale revenue beyond a TTM total of $116,670, coupled with consistent quarterly operating losses exceeding $1.3 million, suggests significant insolvency risk.
Investors should monitor the company's ability to secure non-dilutive capital or achieve clinical milestones, as the current cash burn rate threatens to exhaust the $5.1 million cash position without immediate strategic intervention.

Verdict Logic

the company's precarious financial position is highlighted by a persistent quarterly cash burn that threatens its $5.1 million cash balance, leaving little room for error in its speculative drug discovery model.

BFRGW Growth Metrics

Bullfrog AI Holdings, Inc. Warrants (BFRGW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years126.81%

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM14.54%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM34.52%

Return on Capital

10 Years-194.79%

5 Years-194.79%

3 Years-194.79%

Last Year-185.76%

Peers Comparison

Key metrics vs top competitors for Bullfrog AI Holdings, Inc. Warrants (BFRGW)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
BFRGWBullfrog AI Holdings, Inc. WarrantsCurrent	$0.12	$1.57M	-0.20	—	-5569.61%	-183.04%	—
BFRGBullfrog AI Holdings, Inc. Common Stock	$0.65	$8.48M	-1.04	—	-5205.86%	-217.79%	—
RXRXRecursion Pharmaceuticals, Inc.	$3.52	$1.57B	-2.44	26.92%	-844.46%	-54.32%	—
ABSIAbsci Corporation	$10.89	$1.7B	-12.96	-38.24%	-6450.76%	-63.58%	—
AIXIXiao-I Corporation	$1.99	$1.05M	-0.01	-82.47%	-140.37%	—	—
SDGRSchrödinger, Inc.	$16.86	$1.26B	-11.96	23.29%	-40.6%	-30.85%	—